

Supplementary Table 1:

Immunophenotype of tumours expressing E μ -myc

(Control), *E μ -myc/bcl-2*, *E μ -myc/akt* and *E μ -myc/eIF4E*.

Antigen	Control	Bcl-2	Akt	eIF4E
<u>B-cell antigens</u>				
CD45R	Pos	Pos	Pos	Pos
CD19	Pos	Neg	Neg/Weak	Pos
IgM	Pos	Neg	Neg	Variable
Igk	Pos	Neg	Neg	Pos
CD23(Fc ϵ R)	Neg	Neg	Neg	Neg
CD138	Variable	Neg/Weak	Neg	Variable
<u>T-cell antigens</u>				
CD3	Neg	Neg	Neg	Neg
TCR α/β	Neg	Neg	Neg	Neg
TCR γ/δ	Neg	Neg	Neg	Neg
CD4	Neg	Pos	Pos	Neg
CD5	Neg	Neg	Pos	Neg
CD8a	Neg	Neg/Weak	Neg	Variable

Myeloid antigens

Ly-6G (Gr-1)	Neg	Pos	Neg	Neg
CD11b (Mac-1)	Neg/Weak	Neg/Weak	Weak	Variable
Ly-76 (TER119)	Neg	Neg	Neg	Neg
Ly-71 (F4/80)	Neg	Neg	Pos	Neg
CD41	Neg	Neg	Neg	Neg

Lineage non-specific antigens

CD45	Pos	Pos	Pos	Pos
------	-----	-----	-----	-----

Early antigens

CD34	Neg	Neg	Neg/Weak	Neg
Ly-6A/E (Sca-1)	Neg	Pos	Pos	Neg
CD90 (Thy1)	Variable	Pos	Variable	Neg
CD117 (c-Kit)	Neg	Neg	Neg	Neg

Additional antigens

CD16/32 (FC γ RII/III)	Pos	Variable	Pos	Pos
CD31 (PECAM)	Pos	Pos	Pos	Pos
CD43	Pos	Pos	Variable	Pos
CD59 (Ly-6C)	Neg/Weak	Pos	Pos	Variable
CD69	Neg	Neg	Neg	Pos
CD71 (Transferrin Receptor)	Pos	Pos	Pos	Pos

CD86	Variable	Pos	Pos	Pos
Class II (I-a)	Pos	Pos	Pos	Pos